INTESTINE Vol.22 No.5(8)


特集名 大腸腫瘍の分子生物学
題名 大腸癌化学療法と分子生物学
発刊年月 2018年 09月
著者 川﨑 健太 慶應義塾大学医学部消化器内科
著者 浜本 康夫 慶應義塾大学医学部腫瘍センター
【 要旨 】 大腸癌は世界的に罹患率・死亡率の高い疾患である.一方,分子生物学的な検討においては発癌プロセスの理解もあり,長期にわたり先駆的に研究されている疾患である.その研究過程で開発された分子標的治療薬は殺細胞性抗癌剤のみの治療より生存期間を約10カ月も延長した.さらなる分子生物学の進歩は,5%未満のより希少なフラクションの遺伝子変異を検出可能とし,今後の大腸癌治療の生存期間をさらに延長すると考えられる.本稿では,今までの分子生物学の大腸癌化学療法への貢献を概説しながら,今後の新たな治療標的と臨床応用への取り組みに関してまとめる.
Theme Molecular biology of colorectal tumors
Title Treatment of colorectal cancer and molecular biology
Author Kenta Kawasaki Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University
Author Yasuo Hamamoto Keio Cancer Center, School of Medicine, Keio University
[ Summary ] Colorectal cancer is a devastating disease with high morbidity and mortality rates. It has long been studied for its molecular factors including its relationship to oncogenesis. In fact, molecular targeted therapy obtained through research has prolonged overall survival rates by more than 10 months compared to cytotoxic treatment alone. Further advances in molecular biology have provided for the detection of rare mutations which have been reported in less than 5 % of cases. They are expected to prolong overall survival rates due to colorectal cancer in the near future. We outline the contributions of molecular biology to the development of chemotherapy for colorectal cancer and summarize novel therapeutic targets and clinical applications.
戻る